Par Pharmaceutial (NYSE: PRX) announced that its wholly-owned subsidiary, Kali Laboratories, Inc., has received final approval from the U.S ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE